160 related articles for article (PubMed ID: 25464035)
21. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.
Chang G; Xu S; Dhir R; Chandran U; O'Keefe DS; Greenberg NM; Gingrich JR
Clin Cancer Res; 2010 Nov; 16(22):5390-401. PubMed ID: 21062931
[TBL] [Abstract][Full Text] [Related]
22. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
[TBL] [Abstract][Full Text] [Related]
24. Functional epigenomics identifies genes frequently silenced in prostate cancer.
Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth.
Takeuchi A; Shiota M; Beraldi E; Thaper D; Takahara K; Ibuki N; Pollak M; Cox ME; Naito S; Gleave ME; Zoubeidi A
Mol Cell Endocrinol; 2014 Mar; 384(1-2):117-25. PubMed ID: 24491388
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
[TBL] [Abstract][Full Text] [Related]
27. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
[TBL] [Abstract][Full Text] [Related]
28. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
Wang LG; Beklemisheva A; Liu XM; Ferrari AC; Feng J; Chiao JW
Mol Carcinog; 2007 Jan; 46(1):24-31. PubMed ID: 16921492
[TBL] [Abstract][Full Text] [Related]
29. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
30. HIC1 modulates prostate cancer progression by epigenetic modification.
Zheng J; Wang J; Sun X; Hao M; Ding T; Xiong D; Wang X; Zhu Y; Xiao G; Cheng G; Zhao M; Zhang J; Wang J
Clin Cancer Res; 2013 Mar; 19(6):1400-10. PubMed ID: 23340301
[TBL] [Abstract][Full Text] [Related]
31. The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of
Dudzik P; Trojan SE; Ostrowska B; Zemanek G; Dulińska-Litewka J; Laidler P; Kocemba-Pilarczyk KA
Anticancer Res; 2019 May; 39(5):2395-2403. PubMed ID: 31092432
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
[TBL] [Abstract][Full Text] [Related]
33. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation.
Bott SR; Arya M; Kirby RS; Williamson M
Prostate Cancer Prostatic Dis; 2005; 8(4):321-6. PubMed ID: 16276353
[TBL] [Abstract][Full Text] [Related]
34. Heparanase expression is associated with histone modifications in glioblastoma.
Hong X; Nelson K; Lemke N; Kalkanis SN
Int J Oncol; 2012 Feb; 40(2):494-500. PubMed ID: 22001963
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications.
Zhang C; Li H; Wang Y; Liu W; Zhang Q; Zhang T; Zhang X; Han B; Zhou G
J Hepatol; 2010 Nov; 53(5):889-95. PubMed ID: 20675009
[TBL] [Abstract][Full Text] [Related]
36. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of EphA5 by promoter methylation in human prostate cancer.
Li S; Zhu Y; Ma C; Qiu Z; Zhang X; Kang Z; Wu Z; Wang H; Xu X; Zhang H; Ren G; Tang J; Li X; Guan M
BMC Cancer; 2015 Jan; 15():18. PubMed ID: 25609195
[TBL] [Abstract][Full Text] [Related]
38. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis.
Moretti RM; Montagnani Marelli M; Mai S; Cariboni A; Scaltriti M; Bettuzzi S; Limonta P
Cancer Res; 2007 Nov; 67(21):10325-33. PubMed ID: 17974975
[TBL] [Abstract][Full Text] [Related]
39. Clusterin (CLU) and prostate cancer.
Rizzi F; Bettuzzi S
Adv Cancer Res; 2009; 105():1-19. PubMed ID: 19879420
[TBL] [Abstract][Full Text] [Related]
40. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]